Knight Therapeutics (FRA:04K) Moat Score: 4/10 (As of Jul. 07, 2026)


FRA:04K Knight Therapeutics Inc FRA:04K
72 GF Score
Price €6.10
GF Value €5.27
! 6 Warning Signs
View Full Analysis

What is Knight Therapeutics Moat Score?

Knight Therapeutics FRA:04K +0.83% 72 Moat Score is 4 as of Jul. 07, 2026. GuruFocus rates FRA:04K with a GF Score™ of 72/100 and a GF Value™ of €5.27. The stock has 6 warning signs investors should review. Among 1,032 Drug Manufacturers companies, Knight Therapeutics ranks better than 90.7% on this metric.

Knight Therapeutics has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Knight Therapeutics has Narrow Moat: Knight Therapeutics has a modest moat due to its valuable intellectual property and niche market focus. However, it faces significant competition and lacks strong brand strength or customer loyalty, limiting its moat to a narrow category.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Knight Therapeutics might have Narrow Moat - Discernible but modest moat.

Knight Therapeutics  (FRA:04K) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Knight Therapeutics Moat Score Related Terms

FRA:04K vs ZTS, UTHR: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Knight Therapeutics Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's Moat Score falls into.


FRA:04K
72GF Score
Knight Therapeutics Inc FRA:04K
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Knight Therapeutics (FRA:04K) has a Moat Score of 4 as of Jul. 07, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Knight Therapeutics ranks #96 out of 1032 companies in the Drug Manufacturers industry, placing it in the top 9.3%.
Is Knight Therapeutics' Moat Score too high?
Knight Therapeutics' current Moat Score is 4. Based on the distribution chart, Knight Therapeutics ranks #96 out of 1032 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Knight Therapeutics has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Knight Therapeutics ranks #96 out of 1032 companies for Moat Score. This places Knight Therapeutics in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Knight Therapeutics's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Knight Therapeutics (FRA:04K) has a current Moat Score of 4. The stock's GF Value™ is €5.27, compared to a current price of €6.10 — trading 15.7% above its estimated fair value. The current Moat Score is 4. Knight Therapeutics' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Knight Therapeutics (FRA:04K), the current Moat Score is 4 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Knight Therapeutics (FRA:04K) Overvalued in 2026?

Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued. The current stock price of €6.10 is trading 15.7% above its estimated GF Value™ of €5.27.

Key valuation signals for FRA:04K:

  • Moat Score: 4
  • GF Value™: €5.27 vs. price of €6.10 (15.7% above fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the FRA:04K stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Knight Therapeutics Business Description

Other Exchanges KHTRF:USAGUD:Canada
Address 100 Alexis Nihon Boulevard, Suite 600, Saint-Laurent, QC, CAN, H4M 2P2
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
72GF Score

Get the complete analysis for FRA:04K

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.10
Price
€5.27
GF Value